Nuclear protein in testis (NUT) carcinomas (NC) are a rare, highly aggressive, subset of squamous cell carcinomas, characterized by a translocation involving the NUTM1 gene. Thyroid location of NUT carcinomas has rarely been described.
Methods:
We report here two cases of thyroid NC with NSD3::NUTM1 translocation.
Results:
The first case presented as a very aggressive undifferentiated thyroid carcinoma in a 38-year-old man who died 21 months after the diagnosis. The second case was diagnosed after multiple lymphadenopathy recurrences mainly in the neck in a 37-year-old woman 7 years after total thyroidectomy for papillary thyroid carcinoma with a classic and a solid/trabecular component.
Conclusions:
Our case reports highlight the challenges in diagnosing these exceptional carcinomas. The therapeutic impact of the administration of pharmacological compounds with epigenetic action, in line with the physiopathology of these carcinomas, is also discussed.
Get full access to this article
View all access options for this article.
References
1.
AndertonJ, MorozV, Marec-BérardP, et al.International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours—EURO EWING 2012 protocol. Trials, 2020; 21(1):96; doi: 10.1186/s13063-019-4026-8.
2.
CousinS, BlayJ-Y, GarciaIB, et al.Safety, Pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a phase I/II open-label, dose escalation study. Int J Cancer, 2022; 150(6):993–1006; doi: 10.1002/ijc.33861.
3.
BalochZW, AsaSL, BarlettaJA, et al.Overview of the 2022 WHO Classification of thyroid neoplasms. Endocr Pathol, 2022; 33(1):27–63; doi: 10.1007/s12022-022-09707-3.
GiridharP, MallickS, KashyapL, et al.Patterns of care and impact of prognostic factors in the outcome of NUT midline carcinoma: A systematic review and individual patient data analysis of 119 cases. Eur Arch Otorhinolaryngol, 2018; 275(3):815–821; doi: 10.1007/s00405-018-4882-y.
6.
BauerDE, MitchellCM, StraitKM, et al.Clinicopathologic features and long-term outcomes of NUT midline carcinoma. Clin Cancer Res, 2012; 18(20):5773–5779; doi: 10.1158/1078-0432.CCR-12-1153.
7.
SalatiM, BaldessariC, BonettiLR, et al.NUT midline carcinoma: Current concepts and future perspectives of a novel tumour entity. Crit Rev Oncol Hematol, 2019; 144:102826; doi: 10.1016/j.critrevonc.2019.102826.
8.
ThompsonLDR and FranchiA. New tumor entities in the 4th edition of the World Health Organization classification of head and neck tumors: Nasal cavity, paranasal sinuses and skull base. Virchows Arch Int J Pathol, 2018; 472(3):315–330; doi: 10.1007/s00428-017-2116-0.
9.
TravisWD, BrambillaE, NicholsonAG, et al.The 2015 World Health Organization classification of lung tumors. J Thorac Oncol, 2015; 10(9):1243–1260; doi: 10.1097/JTO.0000000000000630.
10.
DicksonBC, SungY-S, RosenblumMK, et al.NUTM1 gene fusions characterize a subset of undifferentiated soft tissue and visceral tumors. Am J Surg Pathol, 2018; 42(5):636–645; doi: 10.1097/PAS.0000000000001021.
11.
FrenchCA. Pathogenesis of NUT midline carcinoma. Annu Rev Pathol Mech Dis, 2012; 7(1):247–265; doi: 10.1146/annurev-pathol-011811-132438.
12.
AllisonDB, RueckertJ, CorneaV, et al.Thyroid carcinoma with NSD3::NUTM1 fusion: A case with thyrocyte differentiation and colloid production. Endocr Pathol, 2022; 33(2):315–326; doi: 10.1007/s12022-021-09700-2.
13.
AgaimyA, TögelL, StoehrR, et al.NSD3-NUTM1-rearranged carcinoma of the median neck/thyroid bed developing after recent thyroidectomy for sclerosing mucoepidermoid carcinoma with eosinophilia: Report of an extraordinary case. Virchows Arch Int J Pathol, 2021; 479(6):1095–1099; doi: 10.1007/s00428-021-03103-8.
14.
KuoLE, BarlettaJ, SchoenfeldJD, et al.NUT carcinoma of the thyroid: An unusual case with a complete response to treatment. Clin Thyroidol, 2021; 33(1):38–47; doi: 10.1089/ct.2021;33.38-47.
15.
LandaI, IbrahimpasicT, BoucaiL, et al.Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest, 2016; 126(3):1052–1066; doi: 10.1172/JCI85271.
16.
ZhouJ, DuanM, JiaoQ, et al.Primary thyroid NUT carcinoma with high PD-L1 expression and novel massive IGKV gene fusions: A case report with treatment implications and literature review. Front Oncol, 2022; 11:778296; doi: 10.3389/fonc.2021.778296.
17.
FrenchCA, MiyoshiI, KubonishiI, et al.BRD4-NUT fusion oncogene: A novel mechanism in aggressive carcinoma. Cancer Res, 2003; 63(2):304–307. PMID: 12543779.
FrenchCA, RahmanS, WalshEM, et al.NSD3-NUT fusion oncoprotein in NUT midline carcinoma: Implications for a novel oncogenic mechanism. Cancer Discov, 2014; 4(8):928–941; doi: 10.1158/2159-8290.CD-14-0014.
BairRJ, ChickJF, ChauhanNR, et al.Demystifying NUT midline carcinoma: radiologic and pathologic correlations of an aggressive malignancy. Am J Roentgenol, 2014; 203(4):W391–W399; doi: 10.2214/AJR.13.12401.
22.
HuangQW, HeLJ, ZhengS, et al.An overview of molecular mechanism, clinicopathological factors, and treatment in NUT carcinoma. Biomed Res Int, 2019;2019:1018439; doi: 10.1155/2019/1018439.
23.
JungM, KimS, LeeJ-K, et al.Clinicopathological and preclinical findings of NUT carcinoma: A multicenter study. Oncologist, 2019; 24(8):e740–e748; doi: 10.1634/theoncologist.2018-0477.
24.
HaackH, JohnsonLA, FryCJ, et al.Diagnosis of NUT midline carcinoma using a NUT-specific monoclonal antibody:. Am J Surg Pathol, 2009; 33(7):984–991; doi: 10.1097/PAS.0b013e318198d666.
25.
NapolitanoM, VenturelliM, MolinaroE, et al.NUT midline carcinoma of the head and neck: Current perspectives. Onco Targets Ther, 2019; 12:3235–3244; doi: 10.2147/OTT.S173056.
26.
SmelandS, WiebeT, BrosjöO, et al.Chemotherapy in Ewing's sarcoma: The Scandinavian Sarcoma Group experience. Acta Orthop Scand, 2004;75(Suppl 311):87–91; doi: 10.1080/00016470410001708370.
27.
StorckS, KennedyAL, MarcusKJ, et al.Pediatric NUT-midline carcinoma: Therapeutic success employing a sarcoma based multimodal approach. Pediatr Hematol Oncol, 2017; 34(4):231–237; doi: 10.1080/08880018.2017.1363839.
28.
MertensF, WiebeT, AdlercreutzC, et al.Successful treatment of a child with t(15;19)-positive tumor. Pediatr Blood Cancer, 2007; 49(7):1015–1017; doi: 10.1002/pbc.20755.
29.
StathisA, ZuccaE, BekraddaM, et al.Clinical response of carcinomas harboring the BRD4-NUT oncoprotein to the targeted Bromodomain inhibitor OTX015/MK-8628. Cancer Discov, 2016; 6(5):492–500; doi: 10.1158/2159-8290.CD-15-1335.
30.
ShapiroGI, LoRussoP, DowlatiA, et al.A phase 1 study of RO6870810, a novel Bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma. Br J Cancer, 2021; 124(4):744–753; doi: 10.1038/s41416-020-01180-1.
31.
MaherOM, ChristensenAM, YedururiS, et al.Histone deacetylase inhibitor for NUT midline carcinoma: HDACi for NUT midline carcinoma. Pediatr Blood Cancer, 2015; 62(4):715–717; doi: 10.1002/pbc.25350.
